BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34910129)

  • 1. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
    Rahman S; Thomas B; Maynard N; Park MH; Wahedally M; Trudgill N; Crosby T; Cromwell DA; Underwood TJ
    Br J Surg; 2022 Feb; 109(2):227-236. PubMed ID: 34910129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
    Cunningham D; Stenning SP; Smyth EC; Okines AF; Allum WH; Rowley S; Stevenson L; Grabsch HI; Alderson D; Crosby T; Griffin SM; Mansoor W; Coxon FY; Falk SJ; Darby S; Sumpter KA; Blazeby JM; Langley RE
    Lancet Oncol; 2017 Mar; 18(3):357-370. PubMed ID: 28163000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
    N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
    Kuhnle PJ; Israel KF; Menges M
    Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
    Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
    Liu K; Zhang WH; Hu JK
    Br J Surg; 2022 Jul; 109(8):e91. PubMed ID: 35583148
    [No Abstract]   [Full Text] [Related]  

  • 8. Author response to: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
    Rahman SA; Underwood TJ
    Br J Surg; 2022 Jul; 109(8):e92. PubMed ID: 35583142
    [No Abstract]   [Full Text] [Related]  

  • 9. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
    Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
    Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
    BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
    Jagadesham VP; Lagarde SM; Immanuel A; Griffin SM
    Br J Surg; 2017 Mar; 104(4):401-407. PubMed ID: 28072456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone.
    Achiam MP; Jensen LB; Larsson H; Jensen LS; Larsen AC; Holm J; Svendsen LB
    Scand J Surg; 2016 Mar; 105(1):22-8. PubMed ID: 25794689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
    Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
    Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peri-operative chemotherapy in patients with oesophageal and gastro-oesophageal junction cancer - three years of experience.
    Pechačová Z; Zemanová M; Haruštiak T; Vítek P; Fencl P
    Prague Med Rep; 2013; 114(2):57-71. PubMed ID: 23777797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
    Geh JI; Glynne-Jones R; Kwok QS; Banerji U; Livingstone JI; Townsend ER; Harrison RA; Mitchell IC
    Clin Oncol (R Coll Radiol); 2000; 12(3):182-7. PubMed ID: 10942336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
    Bamias A; Cunningham D; Nicolson V; Norman A; Hill M; Nicolson M; O'Brien M; Webb A; Hill A
    Br J Cancer; 1995 Mar; 71(3):583-6. PubMed ID: 7880742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg.
    Haag GM; Byl A; Jäger D; Berger AK
    Oncology; 2017; 92(5):291-298. PubMed ID: 28249280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.